Dimensional Fund Advisors LP increased its position in shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 14.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 6,892,184 shares of the biopharmaceutical company’s stock after buying an additional 849,721 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Achillion Pharmaceuticals were worth $19,505,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of the stock. California State Teachers Retirement System raised its stake in Achillion Pharmaceuticals by 11.9% during the 1st quarter. California State Teachers Retirement System now owns 206,482 shares of the biopharmaceutical company’s stock worth $766,000 after buying an additional 22,017 shares during the period. New York State Common Retirement Fund increased its holdings in Achillion Pharmaceuticals by 24.1% during the 1st quarter. New York State Common Retirement Fund now owns 146,800 shares of the biopharmaceutical company’s stock worth $545,000 after purchasing an additional 28,500 shares in the last quarter. Element Capital Management LLC bought a new stake in Achillion Pharmaceuticals during the 1st quarter worth approximately $163,000. Acadian Asset Management LLC bought a new stake in Achillion Pharmaceuticals during the 2nd quarter worth approximately $135,000. Finally, A.R.T. Advisors LLC increased its holdings in Achillion Pharmaceuticals by 39.7% during the 1st quarter. A.R.T. Advisors LLC now owns 185,913 shares of the biopharmaceutical company’s stock worth $689,000 after purchasing an additional 52,800 shares in the last quarter. 78.36% of the stock is currently owned by institutional investors and hedge funds.
Shares of ACHN opened at $3.13 on Friday. The company has a market cap of $510.00 million, a price-to-earnings ratio of -5.02 and a beta of 1.27. Achillion Pharmaceuticals, Inc. has a 52 week low of $2.33 and a 52 week high of $4.63.
Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. On average, sell-side analysts predict that Achillion Pharmaceuticals, Inc. will post -0.52 earnings per share for the current fiscal year.
ACHN has been the subject of a number of recent research reports. BidaskClub lowered Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday. Zacks Investment Research raised Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 28th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $4.38.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.
See Also: NASDAQ Stock Market Explained
Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.